Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Executive Summary

Obsidian CEO Michael Gilman described the company's technology – which allows CAR-T cells and other therapies to be activated by available small molecule drugs – as being able to modulate the effective yet toxic therapies by dialing down, turning up or shutting off the treatments as needed.

Advertisement

Related Content

Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
Value Unlocked: BMS Buying Padlock For Up To $600m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel